<DOC>
	<DOC>NCT02897999</DOC>
	<brief_summary>The purpose of this dose-escalation study is to assess the safety and pharmacodynamics of single and multiple doses of QBKPN SSI, administered subcutaneously to healthy adult volunteers</brief_summary>
	<brief_title>Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Adjuvants, Immunologic</mesh_term>
	<criteria>Healthy, nonsmoking (at least for 6 months prior to first study drug administration) males or females, 18 to 65 years of age, inclusive at the time of informed consent. Body mass index (BMI) that is within 18.5 30.0 kg/m2, inclusive. Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination Systolic blood pressure between 95140 mmHg, inclusive, and diastolic blood pressure between 5590 mmHg, inclusive, and heart rate between 50100 bpm, inclusive, unless deemed otherwise by the PI/SubInvestigator. QTc interval â‰¤ 450 milliseconds for males and females, unless deemed otherwise Not Clinically Significant by the Principal Investigator/SubInvestigator. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements. Agree not to have a tattoo or body piercing until the end of the study. Agree to practice effective methods of contraception Known history or presence of any clinically significant hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the PI/SubInvestigator. A known history or positive test result for human immunodeficiency virus (HIV), chronic Hepatitis B surface antigen, or Hepatitis C. A positive test result for drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), alcohol test and cotinine. Positive pregnancy test for female subjects. Known history or presence of (1) Alcohol abuse or dependence within one year prior to first study drug administration; (2) Drug abuse or dependence; (3) Hypersensitivity or idiosyncratic reaction to killed wholecell bacterial vaccines or phenol, and/or related substances; (4) Food allergies and/or presence of any dietary restrictions; or (5) Severe allergic reactions (e.g. anaphylactic reactions, angioedema). Recent history (within 8 weeks prior to screening) of travel to or emigration from any country with high incidence for tuberculosis. A positive tuberculin skin (PPD) test result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>